{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:26:39Z","timestamp":1794054399532,"version":"4.8.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Therapeutic application of newly developed oximes is limited due to their adverse effects on different tissues. Within this article, it has been investigated which morphological changes could be observed in Wistar rats after the treatment with increasing doses of selected acetyl cholinesterase reactivators - asoxime, obidoxime, K027, K048, and K075. Subsequently, heart, diaphragm and musculus popliteus were obtained for pathohistological and semiquantitative analysis 24 hrs and 7 days after <jats:italic>im<\/jats:italic> administration of a single dose of 0.1 LD<jats:sub>50<\/jats:sub>, 0.5 LD<jats:sub>50<\/jats:sub>, and 1.0 LD<jats:sub>50<\/jats:sub> of each oxime. Different muscle damage score was based on an estimation scale from 0 (no damage) to 5 (strong damage). In rats treated with 0.1 LD<jats:sub>50<\/jats:sub> of each oxime, muscle fibres did not show any change. The intensive degeneration was found in all muscles after treatment with 0.5 LD<jats:sub>50<\/jats:sub> of asoxime and obidoxime, respectively. Acute toxic muscle injury was developed within 7 days following treatment with 0.5 LD<jats:sub>50<\/jats:sub> and 1.0 LD<jats:sub>50<\/jats:sub> of each oxime, with the highest values in K048 and K075 group (P\u2009&lt;\u20090.001 vs. control and asoxime), respectively. The early muscle alterations observed in our study seem to contribute to the pathogenesis of the oxime-induced toxic muscle injury, which probably manifests as necrosis and\/or inflammation.<\/jats:p>","DOI":"10.1038\/s41598-018-37837-4","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T11:04:47Z","timestamp":1549451087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Toxic Injury to Muscle Tissue of Rats Following Acute Oximes Exposure"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5137-2638","authenticated-orcid":false,"given":"Vesna","family":"Ja\u0107evi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenie","family":"Nepovimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Ku\u010da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"37837_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.tox.2005.06.011","volume":"214","author":"L Szinicz","year":"2005","unstructured":"Szinicz, L. History of chemical and biological warfare agents. Toxicol. 214, 167\u201381 (2005).","journal-title":"Toxicol."},{"key":"37837_CR2","unstructured":"Smart, J. K. History of chemical and biological warfare: an American perspective in Medical Aspects of Chemical and Biological Warfare (eds Sidell, F. R., Takafuji, E. T. & Franz, D. R.) 9\u201386 (Borden Institute, Walter Reed Army Medical Center, Washington DC, USA 1997)."},{"key":"37837_CR3","first-page":"1","volume":"6","author":"S Willingham","year":"2000","unstructured":"Willingham, S. Military Role in U.S. Response to Terrorism Remains Unclear. Nat. Def. Mag. 6, 1\u20137 (2000).","journal-title":"Nat. Def. Mag."},{"key":"37837_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3121\/cmr.2007.701","volume":"5","author":"B Antonijevic","year":"2007","unstructured":"Antonijevic, B. & Stojiljkovic, M. P. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clinic. Med. Res. 5, 71\u201382 (2007).","journal-title":"Clinic. Med. Res."},{"key":"37837_CR5","doi-asserted-by":"crossref","unstructured":"Sidell, F. R. Nerve agents in Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare (eds Sidell, F. R., Takafuji, T. E. & Franz, D. R.) 129\u2013179 (Falls Church, VA, Office of the Surgeon General, U.S. Army 1997).","DOI":"10.21236\/ADA398241"},{"key":"37837_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/0885066603258659","volume":"19","author":"SW Wiener","year":"2004","unstructured":"Wiener, S. W. & Hoffman, R. S. Nerve Agents: A Comprehensive. Review J. Intens. Care. Med. 19, 22\u201337 (2004).","journal-title":"Review J. Intens. Care. Med."},{"key":"37837_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0065-2423(04)38006-6","volume":"38","author":"J Bajgar","year":"2004","unstructured":"Bajgar, J. Organophosphates\/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 38, 151\u2013216 (2004).","journal-title":"Adv. Clin. Chem."},{"key":"37837_CR8","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.2174\/092986709788803088","volume":"16","author":"J Bajgar","year":"2009","unstructured":"Bajgar, J. et al. Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr. Med. Chem. 16, 2977\u20132986 (2009).","journal-title":"Curr. Med. Chem."},{"key":"37837_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.toxlet.2011.04.006","volume":"206","author":"P Masson","year":"2011","unstructured":"Masson, P. Evolution of and perspectives on therapeutic approaches to nerve agent poisoning. Toxicol. Lett. 206, 5\u201313 (2011).","journal-title":"Toxicol. Lett."},{"key":"37837_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.tiv.2006.06.009","volume":"20","author":"CH Dalton","year":"2006","unstructured":"Dalton, C. H. et al. Absorption of the nerve agent VX (O-ethyl-S-[2(di-isopropylamino)ethyl] methylphosphonothioate)through the pig, human and guinea pig skin in vitro. Toxicol. In Vitro 20, 1532\u20131536 (2006).","journal-title":"Toxicol. In Vitro"},{"key":"37837_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.toxlet.2009.07.025","volume":"190","author":"M Jokanovic","year":"2009","unstructured":"Jokanovic, M. Medical treatment of acute poisoning with organophosphorus and carbamate pesticides. Toxicol. Lett. 190, 107\u2013115 (2009).","journal-title":"Toxicol. Lett."},{"key":"37837_CR12","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2174\/1568026611209061775","volume":"12","author":"M Jokanovic","year":"2012","unstructured":"Jokanovic, M. Structure-activity relationship and efficacy of pyridinium oximes in the treatment of poisoning with organophosphorus compounds: a review of recent data. Curr. Top. Med. Chem. 12, 1775\u20131789 (2012).","journal-title":"Curr. Top. Med. Chem."},{"key":"37837_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/01480540601017637","volume":"30","author":"K Kuca","year":"2007","unstructured":"Kuca, K., Jun, D. & Bajgar, J. Currently used cholinesterase reactivators against nerve agent intoxication: comparison of their effectivity in vitro. Drug Chem. Toxicol. 30, 31\u201340 (2007).","journal-title":"Drug Chem. Toxicol."},{"key":"37837_CR14","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s00204-016-1827-3","volume":"90","author":"L Gorecki","year":"2016","unstructured":"Gorecki, L. et al. SAR study to find optimal cholinesterase reactivator against organophosphorus nerve agents and pesticides. Arch. Toxicol. 90, 2831\u20132859 (2016).","journal-title":"Arch. Toxicol."},{"key":"37837_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1023\/A:1024960819430","volume":"28","author":"K Sakurada","year":"2003","unstructured":"Sakurada, K. et al. Pralidoximeiodide (2-pAM) penetrates across the blood-brain barrier. Neurochem. Res. 28, 1401\u20131407 (2003).","journal-title":"Neurochem. Res."},{"key":"37837_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/jat.1457","volume":"29","author":"DE Lorke","year":"2009","unstructured":"Lorke, D. E. & Petroianu, G. A. Minireview: does in-vitro testing of oximes help predict their in-vivo action after paraoxon exposure? J. Appl. Toxicol. 29, 459\u2013469 (2009).","journal-title":"J. Appl. Toxicol."},{"key":"37837_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s002040050100","volume":"68","author":"U Sp\u00f6hrer","year":"1994","unstructured":"Sp\u00f6hrer, U., Thiermann, H., Klimmek, R. & Eyer, P. Pharmacokinetics of the oximes HI 6 and HL\u00f6 7 in a dog after i.m. injection with newly developed dry\/wet autoinjectors. Arch. Toxicol. 68, 480\u2013489 (1994).","journal-title":"Arch. Toxicol."},{"key":"37837_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1023\/A:1015818821686","volume":"8","author":"JW Schlager","year":"1991","unstructured":"Schlager, J. W., Dolzine, T. W., Stewart, J. R., Wannarka, G. L. & Shih, M. L. Operation evaluation of three commercial configurations of atropine\/HI-6 wet\/dry autoinjectors. Pharm. Res. 8, 1191\u20131194 (1991).","journal-title":"Pharm. Res."},{"key":"37837_CR19","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1389557514666140219103138","volume":"14","author":"J Korabecny","year":"2014","unstructured":"Korabecny, J. et al. From pyridinium-based to centrally active acetylcholinesterase reactivators. Mini. Rev. Med. Chem. 14, 215\u2013221 (2014).","journal-title":"Mini. Rev. Med. Chem."},{"key":"37837_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1039\/C6TX00130K","volume":"5","author":"E Nepovimova","year":"2016","unstructured":"Nepovimova, E. et al. A 7-methoxytacrine-4-pyridinealdoxime hybrid as a novel prophylactic agent with reactivation properties in organophosphate intoxication. Toxicol. Res. 5, 1012\u20131016 (2016).","journal-title":"Toxicol. Res."},{"key":"37837_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cbi.2016.04.034","volume":"259","author":"R Sharma","year":"2016","unstructured":"Sharma, R. et al. Synthesis and in-vitro reactivation screening of imidazolium and oximes as reactivators of sarin and VX-inhibited human acetylcholinesterase (hAChE). Chem. Biol. Interact. 259, 85\u201392 (2016).","journal-title":"Chem. Biol. Interact."},{"key":"37837_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.cbi.2012.10.017","volume":"203","author":"JE Chambers","year":"2013","unstructured":"Chambers, J. E., Chambers, H. W., Meek, E. C. & Pringle, R. B. Testing of novel brain-penetrating oxime reactivators of acetylcholinesterase inhibited by nerve agent surrogates. Chem. Biol. Interact. 203, 135\u2013138 (2013).","journal-title":"Chem. Biol. Interact."},{"key":"37837_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cbi.2012.08.014","volume":"203","author":"Z Radic","year":"2013","unstructured":"Radic, Z. et al. Mechanism of interaction of novel uncharged, centrally active reactivators with OP-hAChE conjugates. Chem. Biol. Interact. 203, 67\u201371 (2013).","journal-title":"Chem. Biol. Interact."},{"key":"37837_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cbi.2012.08.019","volume":"203","author":"Z Kovarik","year":"2013","unstructured":"Kovarik, Z. et al. Centrally acting oximes in reactivation of tabun-phosphoramidite AChE. Chem. Biol. Interact. 203, 77\u201380 (2013).","journal-title":"Chem. Biol. Interact."},{"key":"37837_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.toxlet.2011.04.004","volume":"206","author":"MC de Koning","year":"2011","unstructured":"de Koning, M. C., van Grol, M. & Noort, D. Peripheral site ligand conjugation to a non-quaternary oxime enhances reactivation of nerve agent-inhibited human acetylcholinesterase. Toxicol Lett. 206, 54\u201359 (2011).","journal-title":"Toxicol Lett."},{"key":"37837_CR26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrneph.2014.133","volume":"10","author":"S Garattini","year":"2014","unstructured":"Garattini, S. & Perico, N. Drug development: how academia, industry and authorities interact. Nat. Rev. Nephrol. 10, 602\u2013610 (2014).","journal-title":"Nat. Rev. Nephrol."},{"key":"37837_CR27","doi-asserted-by":"publisher","first-page":"16882","DOI":"10.3390\/ijms140816882","volume":"14","author":"V Sepsova","year":"2014","unstructured":"Sepsova, V. et al. Oximes: inhibitors of human recombinant acetylcholinesterase. A structure-activity relationship (SAR) study. Int. J. Mol. Sci. 14, 16882\u201316900 (2014).","journal-title":"Int. J. Mol. Sci."},{"key":"37837_CR28","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/jat.1229","volume":"27","author":"DE Lorke","year":"2007","unstructured":"Lorke, D. E. et al. Entry of two new asymmetric bispyridinium oximes (K-27 and K-48) into the rat brain: comparison with obidoxime. J. Appl. Toxicol. 27, 482\u2013490 (2007).","journal-title":"J. Appl. Toxicol."},{"key":"37837_CR29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.biopha.2010.01.002","volume":"64","author":"O Soukup","year":"2010","unstructured":"Soukup, O. et al. Novel acetylcholinesterase reactivator K112 and its cholinergic properties. Biomed. Pharmacother. 64, 541\u2013545 (2010).","journal-title":"Biomed. Pharmacother."},{"key":"37837_CR30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.33549\/physiolres.932105","volume":"60","author":"O Soukup","year":"2011","unstructured":"Soukup, O. et al. Oxime reactivators and their in vivo and in vitro effects on nicotinic receptors. Physiol. Res. 60, 679\u2013686 (2011).","journal-title":"Physiol. Res."},{"key":"37837_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00204-012-0977-1","volume":"87","author":"O Soukup","year":"2013","unstructured":"Soukup, O., Jun, D., Tobin, G. & Kuca, K. The summary on non-reactivation cholinergic properties of oxime reactivators: the interaction with muscarinic and nicotinic receptors. Arch Toxicol. 87, 711\u2013719 (2013).","journal-title":"Arch Toxicol."},{"key":"37837_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tox.2005.11.003","volume":"219","author":"M Cali\u0107","year":"2006","unstructured":"Cali\u0107, M. et al. In vitro and in vivo evaluation of pyridinium oximes: mode of interaction with acetylcholinesterase, the effect on tabun- and soman-poisoned mice and their cytotoxicity. Toxicol. 219, 85\u201396 (2006).","journal-title":"Toxicol."},{"key":"37837_CR33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF03033319","volume":"9","author":"L Bartosova","year":"2006","unstructured":"Bartosova, L., Kuca, K., Kunesova, G. & Jun, D. The acute toxicity of acetylcholinesterase reactivators in mice in relation to their structure. Neurotox. Res. 9, 291\u2013296 (2006).","journal-title":"Neurotox. Res."},{"key":"37837_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.neuro.2016.05.006","volume":"55","author":"E Antonijevic","year":"2016","unstructured":"Antonijevic, E. et al. Therapeutic and reactivating efficacy of oximes K027 and K203 against a direct acetylcholinesterase inhibitor. Neurotoxicol. 55, 33\u201339 (2016).","journal-title":"Neurotoxicol."},{"key":"37837_CR35","unstructured":"European Medicines Agency. ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/ich-m-3-r2-non-clinical-safety-studies-conduct-human-clinical-trials-marketing-authorization_en.pdf (2008)."},{"key":"37837_CR36","doi-asserted-by":"publisher","first-page":"e5646","DOI":"10.1590\/1414-431X20165646","volume":"49","author":"EL Andrade","year":"2016","unstructured":"Andrade, E. L. et al. Non-clinical studies in the process of new dru development \u2013 Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz. J. Med. Biol. Res. 49, e5646, https:\/\/doi.org\/10.1590\/1414-431X20165646 (2016).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"37837_CR37","unstructured":"EUR-Lex. Regulation (EC) no 1907\/2006 of the European Parliament and of the council of 18 december 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999\/45\/EC and repealing Council Regulation (EEC) No 793\/93 and Commission Regulation (EC) No 1488\/94 as well as Council Directive 76\/769\/EEC and Commission Directives 91\/155\/EEC, 93\/67\/EEC, 93\/105\/EC and 2000\/21\/EC https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A02006R1907-20140410 (2006)."},{"key":"37837_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14429\/dlsj.1.10733","volume":"1","author":"D Swami","year":"2016","unstructured":"Swami, D., Saxena, N., Karade, H. N. & Kumar, P. Comparative toxicity of bis-pyridinium acetamide derivatives in human cell lines and their acute toxicity in Swiss albino mice. Def. Life Sci. J. 1, 149\u2013154 (2016).","journal-title":"Def. Life Sci. J."},{"key":"37837_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.yrtph.2016.07.011","volume":"80","author":"RH Adamson","year":"2016","unstructured":"Adamson, R. H. The acute lethal dose 50 (LD50) of caffeine in albino rats. Reg. Toxicol. Pharmacol. 80, 274\u2013276 (2016).","journal-title":"Reg. Toxicol. Pharmacol."},{"key":"37837_CR40","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1021\/jm070653r","volume":"50","author":"K Musilek","year":"2007","unstructured":"Musilek, K. et al. Design of a potent reactivator of tabun-inhibited acetylcholinesterase-synthesis and evaluation of (E)-1-(4-carbamoylpyridinium)-4-(4-hydroxyiminomethylpyridinium)-but-2-ene dibromide (K203). J. Med. Chem. 50, 5514\u20135548 (2007).","journal-title":"J. Med. Chem."},{"key":"37837_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.yrtph.2014.12.019","volume":"71","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. Relationship between lethal toxicity in oral administration and injection to mice: Effect of exposure routes. Reg. Toxicol. Pharma. 71, 205\u2013212 (2015).","journal-title":"Reg. Toxicol. Pharma."},{"key":"37837_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40360-017-0193-y","volume":"19","author":"K Ku\u010da","year":"2018","unstructured":"Ku\u010da, K. et al. A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesterase. BC Pharmacol. Toxicol. 19, 2\u201310 (2018).","journal-title":"BC Pharmacol. Toxicol."},{"key":"37837_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1515\/aiht-2015-66-2623","volume":"66","author":"S \u017dunec","year":"2015","unstructured":"\u017dunec, S. et al. Comparative determination of the efficacy of bispyridinium oximes in paraoxon poisoning. Arh. Hig. Rada Toksikol. 66, 129\u2013134 (2015).","journal-title":"Arh. Hig. Rada Toksikol."},{"key":"37837_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1742-7843.2008.00249.x","volume":"103","author":"V Pejchal","year":"2008","unstructured":"Pejchal, V. et al. The Influence of Acetylcholinesterase Reactivators on Selected Hepatic Functions in Rats. Basic Clinic. Pharmacol. Toxicol. 103, 119\u2013123 (2008).","journal-title":"Basic Clinic. Pharmacol. Toxicol."},{"key":"37837_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/toxsci\/kfp166","volume":"111","author":"JD Vassallo","year":"2009","unstructured":"Vassallo, J. D. et al. Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin. Toxicol. Sci. 111, 402\u2013412 (2009).","journal-title":"Toxicol. Sci."},{"key":"37837_CR46","doi-asserted-by":"crossref","unstructured":"Brazeau, G. A. Drug induced muscle damage oxidative stress in muscle (eds Reznic, A. Z. et al.) 295\u2013316 (Springer, Basel AG 1998).","DOI":"10.1007\/978-3-0348-8958-2_19"},{"key":"37837_CR47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1097\/BOR.0000000000000108","volume":"26","author":"JD Jones","year":"2014","unstructured":"Jones, J. D., Kirsch, H. L., Wortmann, R. L. & Pillinger, M. H. The causes of drug-induced muscle toxicity. Curr. Opin. Rheumatol. 26, 697\u2013703 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"37837_CR48","first-page":"256","volume":"20","author":"M Moshiri","year":"2017","unstructured":"Moshiri, M. et al. Injury to skeletal muscle of mice following acute and sub-acute pregabalin exposure. Iran. J. Basic Med. Sci. 20, 256\u2013259 (2017).","journal-title":"Iran. J. Basic Med. Sci."},{"key":"37837_CR49","unstructured":"Bender, H. S. Muscle in Veterinary Laboratory Medicine: ClinicalPathology (eds Latimer, K. S, Mahaffey, E. A. & Prasse, K. W.) 260\u2013269 (Iowa State University Press, Ames, IA 2003)."},{"key":"37837_CR50","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0889-857X(21)00069-7","volume":"20","author":"TJ Bohlmeyer","year":"1994","unstructured":"Bohlmeyer, T. J., Wu, A. H. B. & Perryman, M. B. Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum. Dis.Clin. North Am. 20, 845\u2013856 (1994).","journal-title":"Rheum. Dis.Clin. North Am."},{"key":"37837_CR51","first-page":"5","volume":"5","author":"S Sorichter","year":"1999","unstructured":"Sorichter, S., Puschendorf, B. & Mair, J. Skeletal muscle injury induced by eccentric muscle action: Muscle proteins as markers of muscle fibre injury. Exerc. Immunol. Rev. 5, 5\u201321 (1999).","journal-title":"Exerc. Immunol. Rev."},{"key":"37837_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40634-016-0051-7","volume":"3","author":"T Laumonier","year":"2016","unstructured":"Laumonier, T. & Menetrey, J. Muscle injuries and strategies for improving their repair. J. Exp. Orthop. 3, 1\u20139 (2016).","journal-title":"J. Exp. Orthop."},{"key":"37837_CR53","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/cphy.c100092","volume":"1","author":"JG Tidball","year":"2011","unstructured":"Tidball, J. G. Mechanisms of muscle injury, repair, and regeneration. Compr. Physiol. 1, 2029\u20132062 (2011).","journal-title":"Compr. Physiol."},{"key":"37837_CR54","doi-asserted-by":"publisher","first-page":"R345","DOI":"10.1152\/ajpregu.00454.2004","volume":"288","author":"JG Tidball","year":"2005","unstructured":"Tidball, J. G. Inflammatory processes in muscle injury and repair. Am. J.Physiol. Regul. Integr. Comp. Physiol. 288, R345\u2013R353 (2005).","journal-title":"Am. J.Physiol. Regul. Integr. Comp. Physiol."},{"key":"37837_CR55","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1249\/00005768-199507000-00011","volume":"27","author":"JG Tidball","year":"1995","unstructured":"Tidball, J. G. Inflammatory cell response to acute muscle injury. Med. Sci. Sports Exerc. 27, 1022\u20131032 (1995).","journal-title":"Med. Sci. Sports Exerc."},{"key":"37837_CR56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjsm.37.4.284","volume":"37","author":"H Toumi","year":"2003","unstructured":"Toumi, H. & Best, T. M. The inflammatory response: friend or enemy for muscle injury? Br. J. Sports Med. 37, 284\u2013286 (2003).","journal-title":"Br. J. Sports Med."},{"key":"37837_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1113\/jphysiol.2006.118265","volume":"578","author":"JG Tidball","year":"2007","unstructured":"Tidball, J. G. & Wehling-Henricks, M. Macrophages promote muscle membrane repair and muscle fibre growth and regeneration during modified muscle loading in mice in vivo. J. Physiol. 578, 327\u2013336 (2007).","journal-title":"J. Physiol."},{"key":"37837_CR58","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/mt.2015.97","volume":"23","author":"JG Tidball","year":"2015","unstructured":"Tidball, J. G. & Welc, S. S. Macrophage-derived IGF-1 is a potent coordinator of myogenesis and inflammation in regenerating muscle. Mol. Ther. 23, 1134\u20131135 (2015).","journal-title":"Mol. Ther."},{"key":"37837_CR59","first-page":"17","volume":"188","author":"IS McLennan","year":"1996","unstructured":"McLennan, I. S. Degenerating and regenerating skeletal muscles contain several subpopulations of macrophages with distinct spatial and temporal distributions. J. Anat. 188, 17\u201328 (1996).","journal-title":"J. Anat."},{"key":"37837_CR60","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1084\/jem.20070075","volume":"204","author":"L Arnold","year":"2007","unstructured":"Arnold, L. et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J. Exp. Med. 204, 1057\u20131069 (2007).","journal-title":"J. Exp. Med."},{"key":"37837_CR61","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1096\/fj.14-270090","volume":"30","author":"W Zhao","year":"2016","unstructured":"Zhao, W. et al. CX3CR1 deficiency delays acute skeletal muscle injury repair by impairing macrophage functions. FASEB J 30, 380\u2013393 (2016).","journal-title":"FASEB J"},{"key":"37837_CR62","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.imbio.2013.09.001","volume":"219","author":"B Chazaud","year":"2014","unstructured":"Chazaud, B. Macrophages: supportive cells for tissue repair andregeneration. Immunobiol. 219, 172\u2013178 (2014).","journal-title":"Immunobiol."},{"key":"37837_CR63","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1083\/jcb.200212046","volume":"163","author":"B Chazaud","year":"2003","unstructured":"Chazaud, B. et al. Satellite cells attract monocytes and usemacrophages as a support to escape apoptosis and enhance muscle growth. J. Cell. Biol. 163, 1133\u20131143 (2003).","journal-title":"J. Cell. Biol."},{"key":"37837_CR64","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.tem.2015.07.005","volume":"26","author":"P Munoz-Canoves","year":"2015","unstructured":"Munoz-Canoves, P. & Serrano, A. L. Macrophages decide between regenerationand fibrosis in muscle. Trends Endocrinol. Metab. 26, 449\u2013450 (2015).","journal-title":"Trends Endocrinol. Metab."},{"key":"37837_CR65","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm.3869","volume":"21","author":"DR Lemos","year":"2015","unstructured":"Lemos, D. R. et al. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis fibro\/adipogenic progenitors. Nat. Med. 21, 786\u2013794 (2015).","journal-title":"Nat. Med."},{"key":"37837_CR66","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1242\/dev.069088","volume":"13","author":"F Relaix","year":"2012","unstructured":"Relaix, F. & Zammit, P. S. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns to centre stage. Develop. 13, 2845\u20132856 (2012).","journal-title":"Develop."},{"key":"37837_CR67","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.1242\/dev.067587","volume":"138","author":"R Sambasivan","year":"2011","unstructured":"Sambasivan, R. et al. Pax7-expressing satellitecells are indispensable for adult skeletal muscle regeneration. Develop. 138, 3647\u20133656 (2011).","journal-title":"Develop."},{"key":"37837_CR68","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.coph.2006.01.006","volume":"6","author":"CA Collins","year":"2006","unstructured":"Collins, C. A. Satellite cell self-renewal. Curr. Opin. Pharmacol. 6, 301\u2013306 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"37837_CR69","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.tcb.2005.10.007","volume":"15","author":"J Dhawan","year":"2005","unstructured":"Dhawan, J. & Rando, T. A. Stem cells in postnatal myogenesis: molecularmechanisms of satellite cell quiescence, activation and replenishment. Trends Cell. Biol. 15, 666\u2013673 (2005).","journal-title":"Trends Cell. Biol."},{"key":"37837_CR70","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/S0040-4039(03)00538-0","volume":"44","author":"K Kuca","year":"2003","unstructured":"Kuca, K., Bielavsky, J., Cabal, J. & Bielavska, M. Synthesis of a potential reactivator of acetylcholinesterase-1-(4-hydroxyiminomethylpyridinium)-3-(carbamoylpyridinium)propane dibromide. Tetrahed. Lett. 44, 3123\u20133125 (2003).","journal-title":"Tetrahed. Lett."},{"key":"37837_CR71","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1016\/S0960-894X(03)00751-0","volume":"13","author":"K Kuca","year":"2003","unstructured":"Kuca, K., Bielavsky, J., Cabal, J. & Kassa, J. Synthesis of a new reactivator of tabun-inhibited acetylcholinesterase. Bioorg. Med. Chem. Lett. 13, 3545\u20133547 (2003).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"37837_CR72","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jat.1084","volume":"25","author":"K Kuca","year":"2005","unstructured":"Kuca, K. et al. Effective bisquaternary reactivators of tabun-inhibited AChE. J. Appl Toxicol. 25, 491\u2013495 (2005).","journal-title":"J. Appl Toxicol."},{"key":"37837_CR73","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1080\/00032710701588531","volume":"40","author":"D Jun","year":"2007","unstructured":"Jun, D. et al. HPLC analysis of HI\u20106 dichloride and dimethanesulfonate-antidotes against nerve agents and organophosphorus pesticides. Analyt. Lett. 40, 2783\u20132787 (2007).","journal-title":"Analyt. Lett."},{"key":"37837_CR74","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/chromsci\/46.4.316","volume":"46","author":"D Jun","year":"2008","unstructured":"Jun, D. et al. TLC Analysis of intermediates arising during the preparation of oxime HI-6 dimethanesulfonate. J. Chromat. Sci. 46, 316\u2013319 (2008).","journal-title":"J. Chromat. Sci."},{"key":"37837_CR75","first-page":"99","volume":"96","author":"JT Litchfield","year":"1949","unstructured":"Litchfield, J. T. & Wilcoxon, F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96, 99\u2013113 (1949).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"37837_CR76","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jab.2016.05.004","volume":"14","author":"V Ja\u0107evi\u0107","year":"2016","unstructured":"Ja\u0107evi\u0107, V. et al. Effects of fullerenol nanoparticles and amifostine on radiation-induced tissue damages: Histopathological analysis. J. Appl. Biomed. 14, 285\u2013297 (2016).","journal-title":"J. Appl. Biomed."},{"key":"37837_CR77","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.yexmp.2017.03.005","volume":"102","author":"V Ja\u0107evi\u0107","year":"2017","unstructured":"Ja\u0107evi\u0107, V. et al. Fullerenol nanoparticles prevent doxorubicin-induced acute hepatotoxicity in rats. Exp. Mol. Path. 102, 360\u2013369 (2017).","journal-title":"Exp. Mol. Path."},{"key":"37837_CR78","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.3390\/ijms19082370","volume":"19","author":"V Ja\u0107evi\u0107","year":"2018","unstructured":"Ja\u0107evi\u0107, V. et al. The efficacy of amifostine against multiple-dose doxorubicin-induced toxicity in rats. Int. J. Mol. Sci. 19, 2370, https:\/\/doi.org\/10.3390\/ijms19082370 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"37837_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32376-4","volume":"8","author":"L Ne\u017ei\u0107","year":"2018","unstructured":"Ne\u017ei\u0107, L. et al. Simvastatin protects cardiomyocytes against endotoxin-induced apoptosis and up-regulates survivin\/NF-\u03baB\/p65 expression. Sci. Rep. 8, 14652, https:\/\/doi.org\/10.1038\/s41598-018-32376-4 (2018).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37837-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37837-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T05:31:04Z","timestamp":1671255064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-37837-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["37837"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-37837-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1457"}}